investigation showed extensive colonic and ileal Crohn's disease with compatible histological findings and radiological skip lesions.
Case 2-An 82-year-old woman with a four-month history of bloody diarrhoea was shown to have extensive ulcerative colitis on barium enema, confirmed by sigmoidoscopy and biopsy. Oral prednisolone (40 mg/day) failed to produce improvement, and two weeks later her transverse colon became noticeably distended (9 cm transverse diameter on plain abdominal radiograph). She was feverish (38 7°C), with haemoglobin concentration 10-7 g/dl, white cell count 16-7 X 109/1, and albumin concentration 26 g/l.
Intravenous hydrocortisone and blood transfusion produced initial improvement, but 10 days later the diarrhoea worsened and the colon distended again. Faecal samples at and during admission contained a neutralisable cytopathic toxin, and stool culture grew Cl difficile. Intravenous metronidazole 500 mg eight-hourly was begun, and over the next four days the diarrhoea improved and the colonic dilatation disappeared. After eight days of treatment neither faecal toxin nor Cl difficile was detectable. Three weeks later, however, the patient died from a massive pulmonary embolism.
Comment
Acute toxic dilatation of the colon (toxic megacolon) is an uncommon but well-recognised complication of both ulcerative colitis' and Crohn's disease.' The condition is usually a feature of severe and extensive disease and may occur as the presenting feature of previously unrecognised inflammatory bowel disease. Mortality is around 30%, and surgery is often required when medical intervention fails or colonic perforation occurs.' Investigations such as sigmoidoscopy and contrast radiography may be possible triggering factors and should be performed with caution in any patient with severe active disease; nevertheless, toxic dilatation occurs in their absence, and to date no specific aetiological factors have been identified. Cl difficile is now the accepted major aetiological agent of pseudomembranous and antibioticassociated colitis and has been incriminated in relapses of inflammatory bowel disease.3 That the organism was detected in our patients suggests that it may also be relevant in toxic dilatation of the colon. Interestingly, the symptoms in our second patient responded only partially to intravenous steroids with persistence of Cl difficile. Metronidazole produced a rapid and sustained clinical improvement with eradication of toxin and organism in both patients, thus averting potentially hazardous surgery.
We suggest that Cl difficile may be implicated in toxic colonic dilatation complicating acute inflammatory bowel disease, unrelated to antibiotic exposure, and that routine faecal screening for Cl difficile toxin should be performed in all patients with inflammatory bowel disease in relapse. Binder to be more effective. We carried out a double-blind study to assess the effect of ranitidine.
Patients, methods, and results
In a double-blind study 158 consecutive patients presenting to this hospital over 12 months with acute upper gastrointestinal haemorrhage were randomised to receive oral ranitidine 150 mg thrice daily, to maximise inhibition of gastric acid, or a matching placebo tablet. Treatment was started in the casualty department. Patients underwent endoscopy within 24 hours and were maintained on the trial treatment for 10 days. No specific antacids were prescribed. The severity of bleeding was classified as mild (blood loss estimated at less than three units, with no clinical shock), moderate (blood loss of three to six units and tachycardia with or without hypotension), or severe (grossly clinically shocked with tachycardia of over 110 beats/min, hypotension with a systolic pressure less than 95 mm Hg, and estimated blood loss of more than six units). Patients were examined regularly for evidence of rebleeding, which was defined by clinical assessment, taking into account further haematemesis, fresh melaena, sustained tachycardia or hypotension, or an appreciable fall in haemoglobin concentration. Decisions on managing individual cases were made by five doctors attending the patients independently of the trial. A preliminary study showed that absorption of a single 150 mg oral dose of ranitidine was similar in six patients with acute haemorrhage to absorption in normal volunteers and patients with ulcers.
The *p<0-05.
Significant benefit was noted among those with duodenal ulcer who received ranitidine as compared with placebo (p < 0-05). Most peptic ulcers that rebled were in patients aged over 60. Seven patients were withdrawn from the trial: six because they were judged not to be bleeding from the upper gastrointestinal tract and one because of a rash that had probably been present before randomisation. The tendency to rebleed increased with the severity of initial bleeding, but there were similar numbers in the two treatment groups of patients with mild initial bleeds (two rebleeds in 13 patients receiving ranitidine; three in 12 receiving placebo); moderate initial bleeds (five rebleeds in 38 receiving ranitidine; seven in 41 receiving placebo); and severe initial bleeds (seven rebleeds in 25 receiving ranitidine; 11 in 22 receiving placebo). The groups were similar with respect to age, number aged over 60, sex, haemoglobin concentration on admission, and rise in serum urea concentration. The proportions of patients undergoing surgery were similar in the two groups (11 of 76 receiving ranitidine (14 5°h) v 15 of 75 receiving placebo (200%)). Five patients receiving ranitidine (6 6%) and four receiving placebo (5-3°) died.
Comment
This study is the first to have used ranitidine in acute upper gastrointestinal haemorrhage. Although no overall benefit was noted, the incidence of rebleeding in patients with duodenal ulceration was significantly reduced. Since this was not found previously with cimetidine,4 we might speculate that the increased potency of ranitidine5 may be responsible for the difference. This study also emphasises the adverse effects of age and severity of initial bleed on the predisposition to rebleed. Our results with oral ranitidine, which is convenient and safe, are encouraging and indicate that the drug should be evaluated further in this common serious medical condition. Peripheral neuropathy is a recognised complication of hypothyroidism. Skeletal muscles, the intestines, and the urinary tract may all be affected. We report an unusual case in which the patient presented with paralytic ileus and bladder retention, and despite biochemical evidence of severe hypothyroidism physical signs of myxoedema were absent. The patient eventually responded to replacement treatment.
Case report
A 67-year-old woman was admitted with a history of increasing malaise, constipation, difficulty with walking, and urinary incontinence. On examination she was dehydrated and had a distended, tympanic abdomen with scanty bowel sounds. The bladder was palpable above the umbilicus and this was confirmed radiologically (see figure) . She had global muscle wasting with profound weakness of limb and facial muscles. External signs of myxoedema were absent. She had a normochromic, normocytic anaemia (haemoglobin concentration 8 g/dl) due to combined folate (1.1 /Lg/l) and iron (690 /g/l) deficiencies. Plasma urea (22 mmol/l) and creatinine (194 ,tmol/l) concentrations were both raised. Urine microscopy showed red and white blood cells, and urine culture grew Escherichia coli. Intravenous urography indicated bilateral hydronephrosis with a distended bladder. A barium enema showed severe dilatation of the large intestine with no obvious physical obstruction, an appearance typical of intestinal pseudoobstruction. Electromyographic findings were typical of a severe, predominantly motor polyneuropathy. Thyroid function tests indicated severe primary hypothyroidism with a serum thyroxine concentration of < 10 nmolIl, and a raised thyroid-stimulating hormone concentration of 45 mU/l.
We considered her diagnosis to be hypothyroid polyneuropathy affecting her intestines, urinary tract, and skeletal muscles. Despite intravenous rehydration, blood transfusion, urinary catheterisation, and the administration of thyroxine her condition continued to deteriorate. Nasogastric and rectal suction were begun, together with intravenous hyperalimentation and intravenous triiodothyronine (up to 60 pg/day). This regimen had to be continued for eight weeks before the patient could receive a conventional diet, but her recovery thereafter was uninterrupted. The paralytic ileus resolved and micturition returned to normal, as did her gait. Repeat barium studies and intravenous urography showed no abnormality. She was discharged home feeling well, taking only oral thyroxine (200 jig/day).
Comment
Though combined intestinal and urinary tract involvement in hypothyroidism has previously been reported, the combination of "internal myxoedema" together with a skeletal polyneuropathy has not been described. Ord,' in We describe a patient with tetanus who developed a purely motor spastic paraplegia and left facial palsy, both of which resolved completely.
Case report
A 20-year-old man was admitted to hospital in October 1980 with a threeday history of body stiffness and inability to stand and asymmetry of the face for the previous two days. He had injured his right foot 15 days before. There was no history of head injury, discharge from the ears, or eating seeds of Lathyrus sativus. Examination showed a blood pressure of 130/80 mm Hg, lockjaw, abdominal rigidity, and opisthotonos. He was also having frequent tetanic spasms. Facial asymmetry was due to left-sided facial palsy and spasm of facial muscles on the right, giving the appearance of a hemirisus sardonicus. Hearing and taste were normal. Neurological examination showed purely motor, upper motor neurone spastic paraplegia with hyper-
